FCGR3A and neoplasm: ADCP by monocytes and macrophages can be triggered through their surface expression of FcγRIIIA (CD16), FcγRIIA (CD32), or FcγRI (CD64) and can contribute significantly to anti-tumor effects of IgG antibodies, such as rituximab (83–86).